NOTCH1 and acute lymphoblastic leukemia: In the case of intronic SNV‐generated novel 43 amino acid insertion, one potential option would be to develop immune‐based therapies targeting this T‐ALL‐specific neoepitope and prevent “on‐target off‐tumor” side effects that plague other NOTCH1 inhibitors such as the broad‐spectrum gamma‐secretase inhibitors.